DSIP (delta sleep-inducing peptide)

Not FDA-approved Evidence grade C — small or uncontrolled human studies / case series Updated 2026-10-20

This page describes published research and public regulatory records. It is not medical advice. SoluneFit does not sell, supply, or recommend any compound. The SoluneFit app includes a private, on-device tracker for people who want a record of what they and their clinician have already decided — the app neither suggests compounds nor doses.

Also known as: DSIP, emideltide, delta sleep-inducing peptide, delta sleep inducing peptide, emideltide acetate.

Regulatory status

Not approved and not a component of any FDA-approved drug. FDA's briefing for the 24 July 2026 PCAC proposed NOT adding emideltide (free base or acetate) to the 503A bulks list, citing poor characterisation, weak evidence in insomnia, narcolepsy and opioid withdrawal, and no data for SC use [1][2]; PCAC outcome UNVERIFIED: FDA has posted no minutes or vote summary as of 2026-10-20 (non-FDA reports describe a non-binding vote against inclusion). FDA's compounding-risk page lists it as nominated then withdrawn [3]. FDA cited a pharmacy for compounding DSIP as an ineligible bulk substance with no approved application (warning letter, 2020) [6].

What it is

Nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit blood; INN emideltide.

A nine-amino-acid peptide first found in rabbit blood in the 1970s and tested intravenously in small sleep and withdrawal studies in the 1980s-90s. Results were mixed, and it is not registered as a drug in any country FDA searched.

What the published research shows

About 209 people across small IV studies (n=6-18 in insomnia; one open study of 107 in withdrawal); the larger double-blind insomnia trials found weak or no benefit. No studies of SC use.

Published human studies and reports (these describe trial populations, not SoluneFit claims):

Chronic insomnia, double-blind parallel groups (Bes et al. 1992): 16 patients; 25 nmol/kg IV or placebo on 3 afternoons; slightly better sleep efficiency and latency, judged weak and not of major therapeutic benefit.
Severe chronic insomnia (Schneider-Helmert 1987): 14 middle-aged patients, nightly IV injections for 7 nights (30 nmol/kg per FDA); the author reported better sleep and daytime alertness; FDA notes comparison with an external healthy control group.
Opioid and alcohol withdrawal, open-label (Dick et al. 1984, as summarised by FDA): 107 patients (60 opioid): 25 nmol/kg IV up to 6 times a day for up to 6 days; symptoms improved, but anxiety and insomnia returned within 24-72 h of stopping.
Compounding nomination (withdrawn): 1 mg/mL SC injection for narcolepsy, opioid withdrawal and insomnia.

Mechanism, as reported

Not established. It crosses the blood-brain barrier in animals and may release enkephalins, but how it would affect sleep is unclear.

Practical record

Elimination half-life: 0.13 h (confidence: low). About 8 min in human plasma as stated by FDA without a cited study (unverified primary). FDA also cites IV half-lives of 3-6 min in dogs and 2-3 min in rats and a monkey, and 5-10 min in human serum in vitro. The app uses 8 min; treat the curve as a guess.
Studied routes: intravenous, subcutaneous, intranasal.
Typical supply: No approved product. Sold online as 2 mg/mL vials, 5 mg vials and nasal sprays (FDA). A Russian product, Deltaran, mixes emideltide with glycine (approval status not stated by FDA).
Reconstitution: Free base water-soluble at only about 0.5 mg/mL; FDA questions how a 1 mg/mL injection could be made without a co-solvent.
Storage: Powder -20 °C (3 years) or 4 °C (2 years); about 3 weeks at room temperature (supplier data cited by FDA).

Safety signals on record

Reported adverse events: IV use was mostly well tolerated. In the 107-patient withdrawal study, 9 had brief sweating, headache, nausea or vertigo and 3 had serious reactions, including low blood pressure after injection.
Contraindications: None established (no label).
Interactions: It is broken down partly by the enzyme ACE (peptidyl dipeptidase A), so FDA flags a possible interaction with ACE inhibitors such as captopril.
Notes: No SC safety data and no long-term toxicology. FDA notes possible reinforcing (abuse) potential through enkephalin release and immunogenicity concerns for SC use.

Sources

General wellness education, not medical advice. Unapproved compounds have no established dosing, purity standard, or safety profile.

← All compounds